Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Steroid avoidance in renal transplantation using alemtuzumab versus standard basiliximab/MMF regimen
ISRCTN94424606Phase 4Completed
- Sponsor
- Leeds Teaching Hospitals NHS Trust
- Start
- Apr 2006
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 4, randomised, open-label trial of alemtuzumab, basiliximab, tacrolimus and mycophenolate mofetil in Kidney allograft status (RTx) (2 arms), sponsored by Leeds Teaching Hospitals NHS Trust. Primary endpoint: Diethylene triamine pentaacetate isotopic glomerular filtration rate at 12 months. Started Apr 2006; status: completed.
02
Drugs
alemtuzumabbasiliximabtacrolimusmycophenolate mofetil
03
Conditions
Kidney allograft status (RTx)
Beyond the preview
Go deeper on ISRCTN94424606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN94424606.